A Long-Term, Open-label Extension Study of F2695 SR in Adult Patients With Major Depressive Disorder.
Phase of Trial: Phase III
Latest Information Update: 03 Sep 2013
At a glance
- Drugs Levomilnacipran (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions; Registrational
- Sponsors Forest Laboratories
- 19 May 2013 Results will be presented at the American Psychiatric Association (APA) annual meeting, according to a Forest Laboratories media release.
- 18 Jul 2012 Actual end date (June 2012) added as reported by ClinicalTrials.gov.
- 01 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.